Invention Grant
- Patent Title: Agonist of spexin-based galanin type 2 receptor and use thereof
-
Application No.: US15771078Application Date: 2016-11-30
-
Publication No.: US10385098B2Publication Date: 2019-08-20
- Inventor: Jae Young Seong , Jong-Ik Hwang , Dong-Hoon Kim , Gi Hoon Son , Yoo-Na Lee , Seongsik Yun , Arfaxad Reyes-Alcaraz
- Applicant: NEURACLE SCIENCE CO., LTD.
- Applicant Address: KR Seoul
- Assignee: Neuracle Science Co., Ltd.
- Current Assignee: Neuracle Science Co., Ltd.
- Current Assignee Address: KR Seoul
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: KR10-2015-0168555 20151130
- International Application: PCT/KR2016/013950 WO 20161130
- International Announcement: WO2017/095132 WO 20170608
- Main IPC: C07K7/08
- IPC: C07K7/08 ; A61K38/00 ; A61K9/19 ; A61K9/00 ; A61P25/06 ; A61P25/18 ; A61P25/22 ; A61P25/24 ; A61P25/28 ; A61P25/30

Abstract:
The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
Public/Granted literature
- US20180319841A1 AGONIST OF SPEXIN-BASED GALANIN TYPE 2 RECEPTOR AND USE THEREOF Public/Granted day:2018-11-08
Information query